Company Information

  

Address: 6300 DUMBARTON CIRCLE  
City: FREMONT 
State: CA 
Zip Code: 94555 
Telephone: 510-456-3805 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage biotechnology company pioneering the development of novel therapies in the emerging fields of cell therapy and regenerative medicine. We are focused on developing therapies to treat conditions with high unmet medical needs, with an initial focus on the therapeutic areas of neurology and oncology. We have two core technology platforms. The first is a type of stem cell capable of becoming all of the cell types in the human body, a property called pluripotency. The second is a type of cell called "dendritic cells" used to teach cancer patients' immune systems to attack their tumors.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-0.64NAN/E
06/2017-0.75NAN/E
03/2017-0.69NAN/E
12/2016-0.83NAN/E
09/2016-0.76NAN/E
06/2016-0.61NAN/E
03/2016-0.60NAN/E
12/2015-0.42NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.28Total Liab/Total Assets0.31
Net Inc/Total Assets-0.58Total Liab/Inv Cap0.35
Net Inc/Inv Cap-0.65Total Liab/Comm Equity0.15
Pretax Inc/Net Sales-5.44Interest Coverage Ratio-68.26
Net Inc/Net Sales-5.10Curr Debt/Equity0.00
Cash Flow/Net Sales-2.73LTD/Equity0.10
SG&A/NetSales2.23Total Debt/Equity0.10
Asset Utilization   Liquidity  
Net Receivables Turnover24.53Quick Ratio6.11
Inventory TurnoverNACurrent Ratio6.11
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.22Inv/Curr AssetsNA
Net Sales/PP&E1.27  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 1.69 0.32 2.01 1.75
Cost of Goods Sold 0.08 0.02 0.05 0.01
Selling & Admin Exps 2.05 1.85 4.47 2.40
Operating Income -7.06 -8.53 -9.11 -8.53
Interest Exp 0.11 0.11 0.13 0.13
Pretax Income -6.81 -8.73 -6.29 -9.42
Other Income 0.37 -0.09 2.95 -0.75
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -6.81 -8.73 -6.29 -9.35

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 20.72 25.02 32.50 35.07
Receivables - Total NA NA NA 0.00
Inventories - Total NA NA NA NA
Total Current Assets 21.93 26.37 34.16 36.99
Net Property, Plant & Equipment 4.76 5.00 5.21 5.48
Total Assets 43.32 48.56 57.22 61.01
Liabilities        
Accounts Payable 2.37 2.01 2.59 3.86
Debt in Current Liabilities 0.01 0.01 0.01 0.01
Total Current Liabilities 2.38 2.02 2.88 6.05
Long-Term Debt 3.64 3.77 3.88 4.00
Total Liabilities 11.59 11.85 12.76 18.98
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -105.55 -98.74 -90.02 -83.73
Treasury Stock NA NA NA NA
Total Stockholders' Equity 31.73 36.72 44.46 42.03
Total Liabilities and Stockholders' Equity 43.32 48.56 57.22 61.01

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -4.52 -6.98 -7.15 -3.93
Net Cash Provided by Investing Activities 0.12 -0.09 0.01 -0.25
Net Cash Provided by Financing Activities 1.15 0.88 5.40 6.06

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-22.38--
12/20141.22-10.10-0.33
12/20153.58-15.00-0.42
12/20166.95-35.49-0.83
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17719,33417.24




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.